Short Interest in Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Decreases By 86.2%

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the recipient of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 400 shares, a decline of 86.2% from the January 15th total of 2,900 shares. Based on an average trading volume of 14,500 shares, the days-to-cover ratio is currently 0.0 days.

Scinai Immunotherapeutics Stock Performance

Scinai Immunotherapeutics stock traded down $0.02 during midday trading on Thursday, reaching $3.24. 7,880 shares of the company traded hands, compared to its average volume of 18,061. Scinai Immunotherapeutics has a 12 month low of $2.23 and a 12 month high of $8.92. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.16 and a quick ratio of 1.16. The business has a 50 day moving average of $3.47 and a two-hundred day moving average of $3.57. The firm has a market capitalization of $2.75 million, a price-to-earnings ratio of -0.01 and a beta of 2.37.

Scinai Immunotherapeutics (NASDAQ:SCNI) last announced its earnings results on Friday, November 22nd. The company reported $8.40 earnings per share for the quarter.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.